The bleeding edge of decision making in managed health care - Kaiser-Permanente's model for formulary development

Value in Health

Volumn 5, Issue 5, 2002, Pages 383-389

  Campen, David ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE SYSTEM; MANAGED CARE; NOTE; PRIORITY JOURNAL; PUBLICATION; UNITED STATES; ARTICLE; ECONOMICS; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PHARMACOECONOMICS; PHARMACY AND THERAPEUTICS COMMITTEE;

DECISION MAKING, ORGANIZATIONAL; ECONOMICS, PHARMACEUTICAL; FORMULARIES; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MANAGED CARE PROGRAMS; PHARMACY AND THERAPEUTICS COMMITTEE; PROGRAM EVALUATION; UNITED STATES;

EID: 0036741879     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2002.55001.x     Document Type: Note

References (6)

1. Levine S, Campen D, Millares M, Barrueta A. Kaiser Permanente's prescription drug benefit. Health Aff (Millwood) 2000;19:185-90.
2. Hillier PA, Pedula KL. Characteristics of an adult population with newly diagnosed type 2 diabetes: the relation of obesity and age of onset. Diabetes Care 2001;24:1522-7.
3. Schatz M. The efficacy and safety of asthma medications during pregnancy. Semin Perinatol 2001; 25:145-52.
4. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105:S31-8.
5. Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab 2001;27:305-13.
6. Mukherjee D. Risk of Cardiovascular Events associated with Selective COX-2 Inhibitors. JAMA 2001;286:954-9.